Can AI Find the Right Cancer Drug for the Right Patient? This Collaboration Is Putting It to Work
Source: Streetwise Reports  (10/6/26)
Rakovina Therapeutics Inc. (RKV:TSX.V; RKVTF:OTCPK; 7JO0:FSE) partners with Celvion on AI-driven precision strategies for its ATR inhibitor. More >

Sernova and Seraxis Bet on BetaNova to Take Diabetes Cell Therapy Into the Clinic
Source: Streetwise Reports  (10/6/26)
Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) and Seraxis Holdings Inc. are moving toward a merger to form BetaNova Biotherapeutics, with a type 1 diabetes cell therapy trial planned for early 2027. Find out why one analyst says Sernova found the right partner. More >

Nektar's Phase 2b Data Shows Durable Eczema, Alopecia Response
Source: Streetwise Reports  (10/5/26)
Nektar Therapeutics (NKTR:NASDAQ) reports durable Phase 2b responses for rezpegaldesleukin in eczema and alopecia areata, as the Treg-targeted drug advances toward Phase 3. More >

Aldeyra Plans FDRR to Appeal FDA Reproxalap CRL for Dry Eye
Source: Streetwise Reports  (10/2/26)
Aldeyra Therapeutics Inc. (ALDX:NASDAQ) announces intent to submit Formal Dispute Resolution Request appealing March 2026 CRL for reproxalap in dry eye disease. Here is a plain-English guide to the FDA appeal process for investors. More >

Satellos Targets Untapped FSHD Market With FDA-Cleared IND for Phase 2 Trial
Source: Streetwise Reports  (9/29/26)
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) received FDA clearance of its IND application for a planned Phase 2 study of forazapadin in FSHD; US$5M non-dilutive funding and quotes highlight regeneration potential where no therapies exist. More >

Rocket Pharmaceuticals Advances Danon Disease Gene Therapy Trial With FDA Alignment
Source: Streetwise Reports  (9/24/26)
Rocket Pharmaceuticals Inc. (RCKT:NASDAQ) receives FDA alignment to continue its Phase 2 RP-A501 trial for Danon disease, with nine additional patients expected to be treated by mid-2027. More >

Fennec Pharmaceuticals Reports PEDMARK Data Showing Reduced Hearing Loss in Japanese Study
Source: Streetwise Reports  (9/23/26)
Fennec Pharmaceuticals Inc. (FENC:NASDAQ;FRX:TSE) reports Phase 2 STS-J01 results for PEDMARK in Japan, with ASHA-defined hearing loss in 24% of patients versus a 56.4% benchmark. More >

Coya Enrolls 100 Patients in Phase 2/3 ALS Trial of COYA 302
Source: Streetwise Reports  (9/22/26)
Coya Therapeutics reaches 100-patient enrollment in its Phase 2/3 ALSTARS trial for COYA 302 in ALS, with full enrollment and topline data expected soon. Learn key catalysts for investors. More >

Medicus's Pfizer Deal Was Not a Fire Sale: A Strategic Bet on De-Risked ADC Drug
Source: Mike Sheikh  (9/21/26)
Mike Sheikh shares his thoughts on Medicus Pharma Ltd. (MDCX:NASDAQ) after its recent deal with Pfizer Inc. (PFE:NYSE). More >

Coya Therapeutics Advances COYA 302 ALS Trial With 100th Participant
Source: Streetwise Reports  (9/18/26)
Coya Therapeutics Inc. (COYA:NASDAQ) enrolls its 100th participant in the Phase 2/3 ALSTARS trial of COYA 302 for ALS, with topline data expected in early Q2 2027. More >

US Patient Visits Reach 93% of Prior Quarter's Total in Two Months
Source: Streetwise Reports  (9/17/26)
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported 3,625 completed U.S. patient visits in July and August, alongside 1,555 clinical hours as its U.S. operations expanded. More >

Rocket Doctor AI Delivers 3625 U.S. Patient Visits in July and August
Source: Streetwise Reports  (9/17/26)
Rocket Doctor AI reports 3,625 completed U.S. patient visits in the first two months of Q3 2026. The update highlights ongoing U.S. expansion and telehealth momentum for retail investors. More >

Cleantech Firm Expands Breakthrough Wound Solution to Veterans
Source: Streetwise Reports  (9/10/26)
BioLargo Inc. (BLGO:OTCQX) is bringing its FDA-cleared ViaCLYR wound solution to U.S. government and VA-contracted healthcare facilities through a new deal with Spartan Medical. More >

Chart Buy Signals After Co. Targeting U.S. Alzheimer's Market Reports Final Major Regulatory Milestone
Source: Stewart Thomson  (9/10/26)
Technical Analyst Stewart Thomson reviews Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW0:FRA) following its achievement of a major regulatory milestone. More >

BioLargo Subsidiary Secures Spartan Medical Deal for ViaCLYR Government Sales
Source: Streetwise Reports  (9/10/26)
BioLargo subsidiary Clyra enters an exclusive reseller agreement with Spartan Medical for ViaCLYR wound care solution targeting U.S. government facilities and ECAT listing amid expanding wound care demand. More >

Sernova-Seraxis Merger to Create BetaNova with US$10M for T1D Islet Trial
Source: Streetwise Reports  (9/9/26)
Sernova and Seraxis have entered into a definitive agreement to merge and create BetaNova Biotherapeutics, with US$10 million in financing to advance stem cell-derived islet therapy for type 1 diabetes, targeting Phase 1/2 data by mid-2027. More >

Biotechs Combine to Target Type 1 Diabetes Treatment
Source: Streetwise Reports  (9/8/26)
Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) has agreed to merge with privately held Seraxis to form BetaNova Biotherapeutics, a U.S.-based company advancing cell therapies for type 1 diabetes. Find out why one analyst calls the combination a good strategic move. More >

AI Cancer Drug Pipeline Advances as 72% of Budget Shifts to Drug Discovery
Source: Streetwise Reports  (9/3/26)
Rakovina Therapeutics Inc. (RKV:TSX.V) cut its Q2 net loss 41% year over year while advancing three AI-powered cancer drug programs and closing a CA$1.99 million non-brokered private placement after quarter-end. More >

Digital Health Platform Sees US Patient Visits Surge 196% and Quarterly YoY Revenue Jumps 43%
Source: Streetwise Reports  (9/3/26)
Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) reported Q2 revenue of US$734,028 as U.S. patient visits nearly tripled and its in-network coverage expanded to approximately 24 million lives. More >

Rakovina Therapeutics Shifts 72% of Budget to AI Cancer Programs
Source: Streetwise Reports  (9/3/26)
Rakovina Therapeutics allocated 72% of its budget to AI-powered drug discovery in the second quarter of 2026, up from 57% in Q2 2025. See the three AI-supported DDR programs and upcoming milestones for retail investors. More >

Telehealth Platform Delivers 196% U.S. Visit Growth in Q2
Source: Streetwise Reports  (9/3/26)
Rocket Doctor AI reports 43% revenue growth and 196% U.S. patient visit increase in Q2 2026, backed by 24 million covered lives and an expanding payer network. More >

REGENXBIO Faces Clinical Hold on RGX-121 but Duchenne BLA Advances
Source: Streetwise Reports  (8/31/26)
REGENXBIO's RGX-121 gene therapy faces an FDA clinical hold after spinal MRI findings, while the Duchenne muscular dystrophy program remains on track for its Q3 2026 BLA submission, along with wet AMD pivotal data expected in Q4. More >

REGENXBIO Faces FDA Clinical Hold on Hunter Syndrome Gene Therapy
Source: Streetwise Reports  (8/28/26)
REGENXBIO Inc. (RGNX:NASDAQ) faces an FDA clinical hold on RGX-121 after spinal MRI findings in five patients, while its Duchenne and wet AMD programs remain on track. More >

Is This Biopharmaceutical Co. Developing ALS Drug a Buy?
Source: Streetwise Reports  (8/25/26)
Read to find out what analysts think of Houston-based Coya Therapeutics Inc. (COYA:NASDAQ), which is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative, autoimmune, and metabolic diseases. More >

Ultragenyx Delivers First Gene Therapy FDA Approval for GSDIa
Source: Streetwise Reports  (8/25/26)
Ultragenyx earns FDA approval for GENGLYCOS, its first gene therapy for GSDIa in patients aged 8 and older. Phase 3 data showed reduced cornstarch needs, with analyst price targets rising and a September UX111 decision ahead. More >